ABSTRACT: The author reviews the Princess Margaret Hospital (Ontario Cancer Institute) experience with radiation therapy in certain tumours involving the skull base including meningiomas, chordomas, craniopharyngiomas and other less common tumours. Radiation therapy offers an effective supplementary or alternative treatment for such lesions. RESUME: Therapie par radiation des tumeurs envahissantes de la base du crane L'auteur passe en revue 1'experience acquise au Princess Margaret Hospital (Ontario Cancer Institute) avec la therapie par radiation de certaines tumeurs impliquant la base du crane: meningiomes, chordomes, cranio-pharyngiomes et autres. La radiotherapie sert de traitement supplementaire ou alternatif efficace de telles lesions.
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Management of tumours of the skull base poses unique challenges for both surgeon and radiation oncologist. The limits of any single therapeutic modality may be reached early in the course of the disease, and further treatment often involves a combined approach using more than one modality. Tumours arising in the skull base region are many and varied (Table I) . Many have a chronic natural history with or without treatment, and decision making about treatment frequently relies on factors of unknown prognostic influence. Factors entering into treatment decisions, such as the nature of the symptoms, prior history of the illness, the patient's wishes or the physician's previous experience with such cases, are likely to have agreater impact on the final outcome than the skills of the surgeon, radiation oncologist or chemotherapist. These factors, and indeed the endpoints by which the success of therapy is judged, such as quality of life, remain elusive and difficult to quantify. Such considerations, together with the rarity of most skull base tumours, render evaluation of therapeutic policies or techniques an uncertain task at best.
In this context, we must consider the role of radiation therapy in the management of skull base tumours. With a few exceptions (e.g. plasmacytoma, lymphoma, germinoma, metastatic carcinoma), radiation therapy should be regarded as supplemental to surgery, which remains the primary treatment, and which should be as radical as possible without producing undue morbidity. Radiation therapy may be given following surgery; it is a noninvasive yet local therapy, involving no tissue removal or systematic toxicity. The ability of the radiation oncologist to precisely specify the tissue concentration of his 'drug' within the target tissues remains a remote goal, and the efficacy of treatment is variable and difficult to predict. In addition radiation may damage structures in the neighbourhood of the tumour. In addition to conventional cobalt sources, radiation therapy may be administered by means of high energy equipment, such as a photon beam from a linear accelerator. Using computerized imaging techniques to determine beam and couch angles, together with custom made patient immobilization techniques, the radiation beams are made to overlap in a region which is specified to include the tumour. This results in relative sparing of non-involved tissues. Experimental programs in Boston, Berkeley, and Vancouver use cyclotrons to produce charged particles rather than photons. Such techniques may offer important clinical benefit through improved dose localization in the tumour and minimize dosage to nearby structures.
Meningioma
Meningiomas, because they are usually benign and most can be completely removed surgically, are rarely referred to the Ontario Cancer Institute Princess Margaret Hospital which is the radiation therapy centre for approximately four million people in Southern Ontario. Approximately 200 primary intracranial tumours are referred for radiation each year, yet only 102 patients with meningioma were referred in the 25 year period from 1958 to 1985. Of 85 charts reviewed, there were 23 meningiomas involving the skull base. There were fifteen females and eight males. Symptoms most commonly began in the 4th or 5th decade and the patients' ages ranged from 9 to 81. The location of the tumours was not necessarily typical for meningioma, but reflected the selection process for a group of unresectable tumours ( Table 2) . No systematic method of selecting the tim- ing of radiation therapy in relation to the surgery was identified. Eighteen patients received radiation therapy. In five it was elected to withhold treatment and observe the patient. In spite of presumed residual disease, one patient, not radiated, is free of any evidence of progression 19 years later. Table 3 demonstrates that long survivals are possible with any of the various programs tried. However, the lack of proper control groups, and the small patient numbers make it impossible to determine the specific role of radiation or its optimal timing in relation to surgery. No adverse neurological effects of radiation were identified in this review.
Other studies have attempted to document benefit for radiation therapy (Table 4 ), but are subject to similar uncertainties of interpretation. The study by Wara 1 strongly suggests a reduction in recurrence rate in those patients treated with radiation therapy, but patient selection criteria are not stated. The results reported by Wara and by Carella 2 are for all patients with meningioma, not just the subset involving the skull base. Effenterre 3 reported symptomatic improvement in eight patients with meningioma involving the cavernous sinus, but no objective or long term data are provided. Complete disappearance for at least four years of an extradural frontal meningioma 8 cm in diameter has been recorded. 4 Fukui 5, 6 concluded that the angioblastic (hemangiopericytoma) type of meningioma may show a very good response, a conclusion that had previously 910 recommend radiation therapy for meningiomas involving the optic nerve. Petty et al" in a review of twelve patients with incompletely resected meningiomas, eight of which involve the sphenoid region, conclude that radiation therapy delays recurrence and may contribute to prolonged survival.
The following case illustrates that surgery and radiation therapy can be judiciously combined to bring long term tumour control and relief of symptoms to the patient. A 55-year-old woman with left sided blindness and proptosis had a meningioma arising from the greater wing of the sphenoid bone. It was excised together with the involved greater wing, lateral orbital wall, and lateral two thirds of orbital roof, without entering Tenon's capsule. She remained well for 8 years, when left sided pain recurred, and exophthalmos and temporal lobe seizures developed. Conventional tomography showed dense sclerosis of the sphenoid bone and sinus, extending into the orbital roof and cribriform plate. She received cobalt-60 radiation therapy to the anterior quadrant encompassing all involved bone and orbit, to a dose of 50 Gray in 24 fractions in five weeks. The patient's pain subsided, but marked exophthalmos (25 mm) persisted. One year after radiation an enucleation and removal of fibrous tissue was performed. No tumour was found in the surgical specimen. Her symptoms resolved and a CT examination ten years after radiation therapy showed minor soft tissue changes of uncertain significance along the medial aspect of the sphe-noid wing, but no evidence of mass effect or active neoplasm.
It is not possible to draw definite conclusions regarding the role of radiation therapy for meningiomas. At present, we reserve radiation for cases of known residual unresectable tumour, benign or malignant, which clearly demonstrate progression.
Tumours not yet progressing, but which are residual in relatively inaccessible basal locations such as the region of the cavernous sinus or brain stem may also be considered for radiation treatment because of the serious consequences of tumour progression in those sites. Incompletely removed tumours manifesting malignant histologic features, even though their natural history may be fairly long, should probably also be treated.
Other tumours involving the base of skull
Since chordomas are incompletely resectable tumours, they are often radiated. 12 It has been suggested by Cummings 13 that chordomas may be most effectively treated by a regimen of multiple daily fractions. The Ontario Cancer Institute experience with ten clivus chordomas showed a median survival of seven years, and a ten year survival of 30%. This chronic course is typical, and renders difficult evaluation of the short follow-up results of proton beam therapy reported in six patients from Boston. 14 In the management of craniopharyngioma, radiation therapy appears to be useful in controlling cyst formation. In some patients, marked improvement in visual symptoms occurred. Fewer than 10% of 54 patients at the Ontario Cancer Institute showed active disease after radiation therapy. 15 When medical factors render surgery hazardous, or when craniopharyngioma cysts recur, radiation therapy offers a reasonable alternative approach.
Certain other tumours respond well to radiation, and may require no more than surgical biopsy, followed by radiation therapy for their control. Examples include plasmacytoma, 16 eosinophilic granuloma, lymphoma, some hemangiomas, ' 7 glomus tumour, 18 and angiofibroma. 19 Radiation therapy is also effective for palliation of metastatic carcinoma invading the base of the skull, lesions that are not surgically resectable. A review by Vikram 20 concluded that symptomatic relief may be obtained in up to three quarters of such patients, with little morbidity.
CONCLUSION
Radiation therapy offers an effective supplementary, and at times alternative treatment for patients with certain tumours involving the base of the skull, including incompletely resected meningiomas, chordomas and craniopharyngiomas. Our limited experience with these uncommon tumours makes it difficult to draw firm conclusions as to the optimal dose parameters and long term benefits of radiation.
